Share Twitter LinkedIn Facebook Email Fredrik Schjesvold, MD of Oslo University College addresses how this affects clinicians and what is next for research.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read